Essex Investment Management’s Standard BioTools LAB Stock Holding History

Essex Investment Management’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-55,949	Closed	-$689K	–	485
2019 Q2	$689K	Buy	+55,949	New	+$713K	0.09%	269
2015 Q2	–	Sell	-18,339	Closed	-$772K	–	327
2015 Q1	$772K	Sell	18,339 -102	-0.6%	-$4.03K	0.11%	194
2014 Q4	$622K	Sell	18,441 -2,911	-14%	-$82.4K	0.09%	198
2014 Q3	$523K	Sell	21,352 -1,376	-6%	-$38.7K	0.08%	217
2014 Q2	$668K	Sell	22,728 -4,775	-17%	-$153K	0.1%	220
2014 Q1	$1.21M	Sell	27,503 -5,162	-16%	-$227K	0.18%	178
2013 Q4	$1.25M	Sell	32,665 -9,161	-22%	-$270K	0.18%	163
2013 Q3	$918K	Buy	+41,826	New	+$822K	0.14%	185

Other funds holding LAB

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

EIP

Easterly Investment Partners Beverly, Massachusetts $1.97B AUM 25.87% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

ICM

Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Essex Investment Management's LAB Position: Q3 2019 in Review

Essex Investment Management sold out of Standard BioTools (LAB) in Q3 2019, closing a stake of 55,949 shares — an estimated $689K sold.

Essex Investment Management first reported a position in LAB in Q3 2013 and held it in 8 quarters. The position peaked at $1.25M in Q4 2013. 125 funds tracked by Wall St. Rank hold LAB as of Q3 2019.

Essex Investment Management reported no remaining Standard BioTools position as of Q3 2019 after selling out during the quarter.
Essex Investment Management sold 55,949 Standard BioTools shares in Q3 2019, an estimated $689K.
Essex Investment Management first reported a position in Standard BioTools in Q3 2013 and held it in 8 quarters.
Essex Investment Management's Standard BioTools position peaked at $1.25M in Q4 2013.
125 funds tracked by Wall St. Rank held Standard BioTools as of Q3 2019.

Based on Essex Investment Management's 13F filing for Q3 2019, filed 22 Oct 2019.